History
A list of downloadable documents created during development.
Background information
-
-
Appendix A: decision paper presented to the Institute's Guidance Executive
-
Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 106 KB)
-
TA208 Gastric cancer (HER2-positive metastatic) - trastuzumab: review proposal information
-
Appendix A: provisional matrix of stakeholders
-
-
Appendix B: proposal paper presented to the Institute's Guidance Executive
-
Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 366 KB)
-
TA208 Gastric cancer (HER2-positive metatastic) - trastuzumab: press release information
-
Gastric cancer (HER2-positive metastatic) - trastuzumab: equality impact assessment
-
Gastric cancer (HER2-positive metastatic) - trastuzumab: equality impact assessment
-
Gastric cancer (HER2-positive metastatic) - trastuzumab: equality impact assessment (PDF 75 KB)
Gastric cancer (HER2-positive metastatic) - trastuzumab: final appraisal determination
-
Gastric cancer (HER2-positive metastatic) - trastuzumab: final appraisal determination information
-
Gastric cancer (HER2-positive metastatic) - trastuzumab: final appraisal determination
-
Gastric cancer (HER2-positive metastatic) - trastuzumab: final appraisal determination (PDF 301 KB)
-
Gastric cancer (HER2-positive metastatic) - trastuzumab: response to consultee, commentator and public comments on the ACD and comments from website consultation
-
-
Gastric cancer (HER2-positive metastatic) - trastuzumab: consultee and commentator comments on the ACD
-
Gastric cancer (HER2-positive metastatic) - trastuzumab: Cancer Research UK response
-
Gastric cancer (HER2-positive metastatic) - trastuzumab: Cancer Research UK response (PDF 151 KB)
-
Gastric cancer (HER2-positive metastatic) - trastuzumab: Centre for Reviews and Dissemination - ERG response
-
-
Gastric cancer (HER2-positive metastatic) - trastuzumab: Roche response
-
Gastric cancer (HER2-positive metastatic) - trastuzumab: Roche response (PDF 643 KB)
-
Gastric cancer (HER2-positive metastatic) - trastuzumab: Royal College of Nursing response
-
-
Gastric cancer (HER2-positive metastatic) - trastuzumab: Royal College of Physicians/NCRI/RCR/ACP/JCCO response
-
-
Gastric cancer (HER2-positive metastatic) - trastuzumab: Welsh Assembly Government response
-
-
Gastric cancer (HER2-positive metastatic) - trastuzumab: public comments on the ACD
-
Gastric cancer (HER2-positive metastatic) - trastuzumab: comments received from the public through the NICE website
-
-
Gastric cancer (HER2-positive metastatic) - trastuzumab: comments received from the public by letter
-
Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): appraisal consultation
-
Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): appraisal consultation
-
-
Evaluation report
-
Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): pre-meeting briefing
-
-
Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): evidence review group's report
-
-
Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): addendum to the Evidence Review group report
-
-
Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): ERG response to inaccuracies
-
-
Non-manufacturer submissions
-
Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): non-manufacturer submissions
-
-
Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): RCP non-manufacturer statement
-
-
Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): Roche Pharmaceuticals
-
-
Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): NICE clarification letter
-
-
Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): manufacturer response
-
NICE consults on new treatment for metastatic gastric cancer
Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): response to consultee and commentator comments on the provisional matrix
-
Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): response to consultee and commentator comments on the provisional matrix
-
Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): response to consultee and commentator comments on the draft scope
-
Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): response to consultee and commentator comments on the draft scope
-
Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): final scope
-
Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): final scope
-
Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): final scope (PDF 23 KB)